GATC Subsidiary LifeCodexx Appoints Head of Commercial Operations
Former Brahms sales manager boosts LifeCodexx team
"Now that the development of our first test for non-invasive pre-natal diagnostics using Next Generation Sequencing technologies is entering its final phase, we are delighted to be joined by Dr. Burow, an experienced sales expert in the field of prenatal diagnostics. Dr. Burow will energetically assist us to quickly and efficiently establish strategic access to various European key markets," said Dr. Michael Lutz, CEO of LifeCodexx AG.
"I see great potential for the non-invasive sequencing method for prenatal diagnostics developed by LifeCodexx AG. This technology will not only make it possible to provide a risk assessment during the early phase of pregnancy, but also to carry out a real diagnosis and minimize the risk to the health of the mother and the growing foetus associated with invasive methods," added Dr. Martin Burow.
LifeCodexx AG, a subsidiary of GATC Biotech AG, is an innovative biotech company that focuses on the development of molecular diagnostics based on Next Generation Sequencing technologies. The aim is to establish Next Generation Molecular Diagnostics throughout Europe. LifeCodexx currently develops tests for prenatal diagnostics. The company utilizes the parent company's 20 years of sequencing experience as well as its laboratories, which is the European leader with a total capacity of more than 2 terabases per year. GATC Biotech holds a majority stake in LifeCodexx AG.